Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392)

Bipolar Disorders
Berit X CarlsonRonald Marcus

Abstract

To evaluate the efficacy and safety of aripiprazole (ARI) plus lamotrigine (LTG) compared with placebo (PBO) plus LTG, for long-term treatment in bipolar I disorder patients with a recent manic/mixed episode. After a 9-24 week stabilization phase receiving single-blind ARI (10-30 mg/day) plus open-label LTG (100 or 200 mg/day), patients maintaining stability (Young Mania Rating Scale/Montgomery-Åsberg Depression Rating Scale total scores ≤ 12) with ARI+LTG for eight consecutive weeks were randomized to continue on double-blind ARI + LTG or to receive PBO + LTG, after removing ARI from ARI + LTG treatment, and followed up for 52 weeks. The primary outcome measure was time from randomization to relapse into a manic/mixed episode. A total of 787 patients entered the stabilization phase, and 351 were randomized to ARI + LTG (n = 178) or PBO + LTG (n = 173). ARI + LTG yielded a numerically longer time to manic/mixed relapse than PBO + LTG, but it was not statistically significant [hazard ratio (HR) = 0.55; 95% confidence interval (CI): 0.30-1.03; p = 0.058]. The estimated relapse rates at Week 52 were 11% for ARI + LTG and 23% for PBO + LTG, yielding a number needed-to-treat of nine (95% CI: 5-121). The three most common adverse eve...Continue Reading

References

Nov 1, 1978·The British Journal of Psychiatry : the Journal of Mental Science·R C YoungD A Meyer
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Dec 3, 1999·BMJ : British Medical Journal·D G Altman, P K Andersen
Apr 26, 2001·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·R S McIntyreS H Kennedy
Jul 24, 2001·PharmacoEconomics·C E BegleyL Bryant-Comstock
Jun 14, 2002·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Jun 18, 2002·The Journal of Pharmacology and Experimental Therapeutics·Kevin D BurrisPerry B Molinoff
Jun 5, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David A ShapiroRichard Mailman
Aug 29, 2003·The American Journal of Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Nov 25, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseUNKNOWN Lamictal 605 Study Group
Nov 26, 2003·The American Journal of Psychiatry·Mauricio TohenRoss J Baldessarini
Jan 8, 2004·European Journal of Pharmacology·Shaun JordanC Anthony Altar
Apr 2, 2004·The British Journal of Psychiatry : the Journal of Mental Science·Mauricio TohenJoseph R Calabrese
Apr 21, 2004·The Journal of Clinical Psychiatry·Guy M GoodwinRobert Leadbetter
Jul 15, 2005·The Journal of Clinical Psychiatry·Trisha SuppesUNKNOWN Texas Consensus Conference Panel on Medication Treatment of Bipolar Disorder
May 4, 2006·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Oct 2, 2007·European Psychiatry : the Journal of the Association of European Psychiatrists·Antoni Sicras-MainarRuth Navarro-Artieda
Oct 27, 2007·The Journal of Clinical Psychiatry·Paul E KeckUNKNOWN Aripiprazole Study Group
Apr 22, 2008·Journal of Psychiatric Research·Terence A KetterJulie C Bonner
Oct 4, 2008·European Journal of Pharmacology·Yoshihiro TadoriTetsuro Kikuchi
Feb 10, 2009·The Journal of Clinical Psychiatry·Marc L M van der LoosUNKNOWN LamLit Study Group
Feb 10, 2009·The Journal of Clinical Psychiatry·Michael E Thase
Mar 31, 2009·Journal of Psychopharmacology·G M Goodwin, UNKNOWN Consensus Group of the British Association for Psychopharmacology
Apr 7, 2009·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeSiegfried Kasper

❮ Previous
Next ❯

Citations

May 25, 2012·European Archives of Psychiatry and Clinical Neuroscience·Konstantinos N FountoulakisEduard Vieta
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
Oct 15, 2014·Expert Opinion on Investigational Drugs·Maria Francesca Moro, Mauro Giovanni Carta
Oct 26, 2012·CNS Neuroscience & Therapeutics·Pierre Alexis GeoffroyFrank Bellivier
Jun 19, 2013·Psychiatry and Clinical Neurosciences·Shigenobu KanbaUNKNOWN Committee for Treatment Guidelines of Mood Disorders, Japanese Society of Mood Disorders, 2012
Oct 29, 2015·Case Reports in Psychiatry·Milena Pereira Pondé, Antonio Carlos Cruz Freire
Mar 14, 2013·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN WFSBP Task Force on Treatment Guidelines for Bipolar Disorders
May 16, 2014·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz Grunze, Jean Michel Azorin
Apr 19, 2017·CNS Spectrums·Alessandro CuomoAllan H Young
Jun 28, 2017·Progress in Neuro-psychopharmacology & Biological Psychiatry·Dian-Jeng LiPhilip Chik-Keung Chow
Aug 31, 2019·Drugs·Jean-Michel Azorin, Nicolas Simon
Dec 6, 2019·The International Journal of Neuropsychopharmacology·Konstantinos N FountoulakisHans Jurgen Moeller
Oct 22, 2011·Current Medical Research and Opinion·Guy M GoodwinEduard Vieta
Nov 4, 2017·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Heinz GrunzeUNKNOWN Members of the WFSBP Task Force on Bipolar Affective Disorders Working on this topic
Apr 19, 2017·International Journal of Psychiatry in Clinical Practice·Felix BetzlerStephan Köhler
May 8, 2021·Acta Psychiatrica Scandinavica·Andrea AmerioS Nassir Ghaemi
Aug 17, 2021·Frontiers in Endocrinology·Helene SpeyerJesper Krogh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.